News | Radiation Oncology | September 29, 2020

ACR Joins ASTRO in Urging CMS, Congress for Changes to RO Model

he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images

September 29, 2020 — On Sept. 18, 2020, the Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule. The final rule includes a mandatory radiation oncology (RO) Model and End-Stage Renal Disease Treatment Choices Model. CMS believes these models will further their goal of shifting away from payment for volume of services alone and toward paying for value and outcomes. The RO Model will qualify as an advanced alternative payment model under the Quality Payment Program.

The RO Model will begin Jan. 1, 2021 and will run through Dec. 31, 2025. Certain radiation therapy (RT) providers and RT suppliers that furnish RT services within randomly selected Core Based Statistical Areas (geographic areas determined by zip code) are required to participate in the RO Model. The RO Model will include 30% of RO episodes in eligible geographic areas. The list of mandatory participants can be found on the RO Model website under “Participating Zip Code List.”

Under the RO Model, Medicare will pay participating providers and suppliers a prospective, site-neutral, episode-based payment for specified technical and professional RT services furnished during a 90-day episode to Medicare fee-for-service beneficiaries diagnosed with 16 different cancer types. An episode will only be triggered if there is an initial treatment planning service and at least one radiation treatment service within 28 days. Furthermore, another episode may not be triggered until at least 28 days after the previous episode has ended, referred to as the “clean period.” The base payment amounts for RT services included in the model will be the same for hospital outpatient departments and freestanding radiation therapy centers.

The American College of Radiology (ACR) will join the American Society for Radiation Oncology (ASTRO) in urging CMS and Congress to significantly delay the start date of the RO Model. Despite recommendations from ASTRO and the ACR to allow providers at least six months from the publication of the final rule to implementation due to the impacts of the COVID-19 public health emergency, CMS’ final rule only allows providers three and a half months to prepare for implementation. On Sept. 18, ASTRO issued a statement calling for additional reforms to the model along with delay in implementation. ASTRO stated that although mandatory participation representing 30% of eligible RO episodes is a positive step from the proposed 40%, this final rule goes too far for an untested model. The ACR strongly supports ASTRO’s statement and will be partnering in advocacy efforts.

Read the ACR initial summary on the model.

Related Radiation Oncology Content:

ASTRO responds to CMS Radiation Oncology Model

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...